• news.cision.com/
  • CLS/
  • CLS enters the urology market in the Baltic states in collaboration with JSC Real Fusion, Vilnius Lithuania

CLS enters the urology market in the Baltic states in collaboration with JSC Real Fusion, Vilnius Lithuania

Report this content

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announced it has entered into a non-exclusive distribution agreement with JSC Real Fusion to market and sell CLS products in the Baltic States of Lithuania, Latvia and Estonia. The agreement will enable Real Fusion to not only directly sell and distribute CLS products but also to offer leasing agreements and conduct product evaluation programs and studies in the markets covered by the agreement.

“We see great potential for the commercial introduction of CLS second-generation TRANBERG® Thermal Therapy Systems for image guided laser ablation of localized prostate cancer in our markets”, says mr. Gediminas Česnavičius, CEO of JSC Real Fusion. “Our clinical partners recognize the added value of being able to perform both image-guided targeted biopsies and, in the case of diagnosed localized cancer, image guided focused laser ablation with use the common standardized workflow CLS products offer.”


"Real Fusion has proven to be a reliable partner for clinics in the Baltic states and already offers solutions for precise image-guided prostate biopsies. Expanding their offering from biopsy to minimal invasive focal laser ablation treatment is the next logical step” says Perjan Pleunis, VP Sales in Europe at CLS. “Through this combined offering, patients can now be offered fast, precise and gentle minimally invasive prostate procedures by allowing medical teams to work within a well-integrated setting.”

About prostate cancer

About 1,400,000 new cases per year of prostate cancer are reported worldwide with approximately 350.000 of them within EU. Although the landscape of prostate cancer treatment shows several treatment options, there is still an important unmet need for patients with localized prostate cancer who progressed to intermediate risk stage. The currently available surgical options show significant risks and side effects related to urinary and erectile functions and quality of life.


For more information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

E-mail: dan.mogren@clinicallaser.com




Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. All components of the TRANBERG®|Thermal Therapy Systems have received EU-wide regulatory approval as medical devices (CE-marked class II) for the treatment of soft tissue lesions. CLS is developing its systems to get CE-mark class III for disposable TRANBERG laser applicators to be used in brain as well as expanding the current CE-mark for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se. 

For more information about CLS, please visit the Company's website: www.clinicallaser.se


About JSC Real Fusion

At JSC Real we are driven by the desire to innovate and improve the quality of human lives. Our mission is to bring medical innovations closer to healthcare providers, empowering them on their journey towards expanding precision medicine, transforming care delivery, and improving the overall patient experience. We do this by introducing innovative technologies and new medical solutions to healthcare professionals. Likewise, we support them in every step of the process though educational trainings, consultations and sharing best medical practices.

For more information about Real Fusion, please visit the Company's website: https://realfusion.eu/